Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 2
  • 51
  • 11
  • 670
  • 927
  • 606
  • 5
  • 39
  • 887

Found 931 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 40423 A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

99 years and younger
All genders
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD). We would like to rely on NMDP IRB as the IRB of record for this study.
Learn More

UPCC 32423 An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, A CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Direc

99 years and younger
All genders
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy for the treatment of relapsed or refractory large B-cell lymphoma.
Learn More

UPCC 47423:A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

99 years and younger
All genders
TrAVeRse is a multicenter, open-label, randomized, Phase II study of AVR in treatment naive MCL participants. The primary objective is to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at end of AVR induction will be randomized …
Learn More

UPCC 09818: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

99 years and younger
All genders
The main purpose of this study is to collect information to determine if a medicine called enfortumab vedotin (EV) is effective, safe and comparable to the docetaxel or paclitaxel for cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread …
Learn More

Corrona PsA-SpA Registry

99 years and younger
All genders
Request to rely on New England Institutional Review Board Request to rely on New England Institutional Review Board Request to rely on New England Institutional Review Board
Learn More

FES in Uterine Cancer

99 years and younger
All genders
Primary Objectives Evaluate utility of FES PET/CT to detect estrogen receptor (ER+) uterine cancer lesions in patients with recurrent or metastatic uterine cancer Secondary Objectives Evaluate utility of FES PET/CT compared to standard axial cross-sectional imaging and/or FDG PET/CT when available to establish tumor heterogeneity and staging Correlate FES uptake …
Learn More

BCG at home

99 years and younger
All genders
The long-term goal of our research program is to identify and target the mechanisms by which innovations in care delivery may facilitate compliance with guideline-concordant care and access to care for early and late stage bladder cancer patients. The objective in this proposal is to evaluate a novel delivery model …
Learn More

UPCC 12023: Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation

99 years and younger
All genders
Please refer to Protocol Section 2 (Study Hypothesis/Objectives). Please refer to Protocol Section 3.5 (Primary Endpoints). Please refer to Protocol Section 3.6 (Secondary Endpoints).
Learn More

CAH Treatment

99 years and younger
All genders
To evaluate the safety and tolerability of CRN04894 Change from Baseline in morning (before 11:00 AM) serum A4 (androstenedione) at Week 12. Change from Baseline in morning (before 11:00) serum 17-OHP (17-hydroxyprogesterone) at Week 12.
Learn More

UPCC 18122: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus In Patients With Estrogen Receptor-Positive, Her2-Negative, Locally Advanced

99 years and younger
All genders
This study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6is and endocrine therapy, either in the locally …
Learn More
641 - 650 of 931